Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q19596315> ?p ?o }
Showing triples 1 to 66 of
66
with 100 triples per page.
- Q19596315 subject Q7145142.
- Q19596315 subject Q8372195.
- Q19596315 subject Q8570773.
- Q19596315 subject Q8645495.
- Q19596315 subject Q8887197.
- Q19596315 abstract "Cebranopadol (GRT-6005) is a novel opioid analgesic of the benzenoid class which is currently under development internationally by Grünenthal, a German pharmaceutical company, and its partner Depomed, a pharmaceutical company in the United States, for the treatment of a variety of different acute and chronic pain states. As of November 2014, it is in phase III clinical trials. Cebranopadol is unique in its mechanism of action as an opioid, binding to and activating all four of the opioid receptors; it acts as a full agonist of the nociceptin receptor (Ki = 0.9 nM; EC50 = 13.0; IA = 89%), μ-opioid receptor (Ki = 0.7 nM; EC50 = 1.2; IA = 104%), and δ-opioid receptor (Ki = 18 nM; EC50 = 110; IA = 105%), and as a partial agonist of the κ-opioid receptor (Ki = 2.6 nM; EC50 = 17; IA = 67%). The ED50 values of 0.5-5.6 µg/kg when introduced IV & 25.1 µg/kg after oral administration.Cebranopadol shows highly potent and effective antinociceptive and antihypertensive effects in a variety of different animal models of pain. Notably, it has also been found to be more potent in models of chronic neuropathic pain than acute nociceptive pain compared to selective μ-opioid receptor agonists. Relative to morphine, tolerance to the analgesic effects of cebranopadol has been found to be delayed (26 days versus 11 days for complete tolerance). In addition, unlike morphine, cebranopadol has not been found to affect motor coordination or reduce respiration in animals at doses in or over the dosage range for analgesia. As such, it may have improved and prolonged efficaciousness and greater tolerability in comparison to currently available opioid analgesics.As an agonist of the κ-opioid receptor, cebranopadol may have the capacity to produce psychotomimetic effects and other adverse reactions at sufficiently high doses, a property which could potentially limit its practical clinical dosage range.".
- Q19596315 atcPrefix "None".
- Q19596315 casNumber "863513-91-1".
- Q19596315 iupacName "(1r,4r)-6’-fluoro-N,N-dimethyl-4-phenyl-4’,9’-dihydro-3’H-spiro[cyclohexane-1,1’-pyrano[3,4-b]indol]-4-amine".
- Q19596315 pubchem "11848225".
- Q19596315 thumbnail Cebranopadol_structure.png?width=300.
- Q19596315 wikiPageExternalLink results?term=cebranopadol&Search=Search.
- Q19596315 wikiPageExternalLink 265600020.jsp.
- Q19596315 wikiPageWikiLink Q1088113.
- Q19596315 wikiPageWikiLink Q1425425.
- Q19596315 wikiPageWikiLink Q14897645.
- Q19596315 wikiPageWikiLink Q14911924.
- Q19596315 wikiPageWikiLink Q14911984.
- Q19596315 wikiPageWikiLink Q153838.
- Q19596315 wikiPageWikiLink Q16991690.
- Q19596315 wikiPageWikiLink Q17145461.
- Q19596315 wikiPageWikiLink Q173235.
- Q19596315 wikiPageWikiLink Q18030283.
- Q19596315 wikiPageWikiLink Q183.
- Q19596315 wikiPageWikiLink Q19903375.
- Q19596315 wikiPageWikiLink Q2047938.
- Q19596315 wikiPageWikiLink Q213907.
- Q19596315 wikiPageWikiLink Q2463100.
- Q19596315 wikiPageWikiLink Q2585693.
- Q19596315 wikiPageWikiLink Q2734305.
- Q19596315 wikiPageWikiLink Q286136.
- Q19596315 wikiPageWikiLink Q30.
- Q19596315 wikiPageWikiLink Q30612.
- Q19596315 wikiPageWikiLink Q3271540.
- Q19596315 wikiPageWikiLink Q389934.
- Q19596315 wikiPageWikiLink Q414299.
- Q19596315 wikiPageWikiLink Q416827.
- Q19596315 wikiPageWikiLink Q421797.
- Q19596315 wikiPageWikiLink Q427523.
- Q19596315 wikiPageWikiLink Q472287.
- Q19596315 wikiPageWikiLink Q507443.
- Q19596315 wikiPageWikiLink Q575890.
- Q19596315 wikiPageWikiLink Q7050446.
- Q19596315 wikiPageWikiLink Q7145142.
- Q19596315 wikiPageWikiLink Q7180990.
- Q19596315 wikiPageWikiLink Q7256512.
- Q19596315 wikiPageWikiLink Q770260.
- Q19596315 wikiPageWikiLink Q7814214.
- Q19596315 wikiPageWikiLink Q7825858.
- Q19596315 wikiPageWikiLink Q81938.
- Q19596315 wikiPageWikiLink Q8372195.
- Q19596315 wikiPageWikiLink Q8570773.
- Q19596315 wikiPageWikiLink Q8645495.
- Q19596315 wikiPageWikiLink Q8887197.
- Q19596315 atcPrefix "None".
- Q19596315 casNumber "863513".
- Q19596315 iupacName "-6".
- Q19596315 pubchem "11848225".
- Q19596315 type ChemicalSubstance.
- Q19596315 type Drug.
- Q19596315 type ChemicalObject.
- Q19596315 type Thing.
- Q19596315 type Q8386.
- Q19596315 comment "Cebranopadol (GRT-6005) is a novel opioid analgesic of the benzenoid class which is currently under development internationally by Grünenthal, a German pharmaceutical company, and its partner Depomed, a pharmaceutical company in the United States, for the treatment of a variety of different acute and chronic pain states. As of November 2014, it is in phase III clinical trials.".
- Q19596315 label "Cebranopadol".
- Q19596315 depiction Cebranopadol_structure.png.